Operating Principal

Flagship Pioneering has appointed Eric Topol as Academic Advisor to advance its Preemptive Health and Medicine Initiative. Dr Topol will guide efforts to develop interventions for chronic conditions including cancer, cardiometabolic disorders, immune system diseases and neurodegenerative conditions. Dr Topol is founder and director of the Scripps Research Translational Institute and a globally recognised leader in individualised medicine. His work has pioneered the integration of genomics, large-scale data and artificial intelligence for more precise and proactive care. Flagship's initiative aims to transform healthcare from reactive treatment to predicting and preventing disease before it develops. Dr Topol will collaborate with scientist-entrepreneurs across Flagship's portfolio to shape research and development strategies. He has published over 1,300 peer-reviewed articles and authored four bestselling books on the future of medicine.

Flagship Pioneering appoints Adrian Rawcliffe as CEO-Partner and CEO of Etiome. Adrian "Ad" Rawcliffe Flagship Pioneering, a scientific innovation engine for transformative platforms and products, and Etiome, a Flagship Pioneering company redefining how we detect and preempt disease progression, today announced that Adrian "Ad" Rawcliffe has joined Flagship Pioneering as CEO-Partner and Etiome as Chief Executive Officer. "Ad is an accomplished executive whose leadership has consistently advanced breakthrough science into meaningful impact," said Noubar Afeyan, Ph.D., Co-founder of Etiome and Founder and CEO of Flagship Pioneering. "His ability to guide companies through moments of transformation coupled with his commitment to pioneering new therapeutic approaches position him well to accelerate Etiome's mission to pioneer preemptive healthcare." Rawcliffe is a seasoned biotechnology leader with more than two decades of experience steering high-growth organizations through scientific, strategic, and financial inflection points. He most recently served as CEO of Adaptimmune Therapeutics, where he led the registration of the first engineered TCR T-cell therapy for a solid tumor, orchestrated multiple strategic partnerships and M&A activities, and raised approximately $1.3B through a blend of capital markets and business development. Prior, as CFO, he guided Adaptimmune through its IPO and helped grow the company to more than 500 employees. Before Adaptimmune, he spent more than 15 years at GSK in senior global roles, including SVP of Finance for North American Pharmaceuticals, SVP of Worldwide Business Development and R&D Finance, where he pioneered GSK's first option-based R&D partnership model and led numerous external innovation and venture initiatives, and Managing Partner and President of SR One. Avak Kahvejian, Ph.D., Founding CEO and Director of Etiome, President of Flagship Labs, and General Partner at Flagship Pioneering, said, "Ad is joining Etiome at a critical inflection point as we scale our Temporal Biodynamics(TM) platform across key disease areas of unmet need. His leadership will accelerate Etiome's efforts to transform our discoveries into medicines that change the course of disease." Rawcliffe added, "The ability to map the progression of disease and intervene in the right people at the right time opens a powerful new frontier for medicine. I'm energized by the opportunity to work with this exceptional team to translate these insights into a new generation of disease-modifying therapies, redefining disease, therapeutic intervention, and the patient experience." About Flagship Pioneering Flagship Pioneering invents and builds platform companies, each with the potential for multiple products that transform human health, sustainability and beyond. Since its launch in 2000, Flagship has originated and fostered more than 100 scientific ventures, operating with $14 billion of assets under its direction as of its latest capital raise, announced in July 2024. The current Flagship ecosystem comprises more than 40 companies, including Foghorn Therapeutics, Generate Biomedicines, Inari, Indigo Agriculture, Lila Sciences, Moderna, Sana Biotechnology, Tessera Therapeutics and Valo Health. About Etiome Etiome is redefining how we detect and preempt disease progression to build a healthier future for patients with chronic and progressive diseases. Its Temporal Biodynamics(TM) platform is the first end-to-end technology to characterize disease with increased resolution over time and accelerate the development of preemptive medicines that promise better health outcomes. By revealing the dynamic molecular programs that define each stage of disease evolution, the platform drives the discovery of temporally informed therapeutic targets and biomarkers. These insights guide the development of Biostaged Medicines designed to halt or reverse disease before it becomes debilitating and irreversible. Etiome was founded by Flagship Pioneering in 2021. For more information, visit www.etiome.bio or follow us on LinkedIn and X.

Flagship Pioneering unveils Expedition Medicines to expand the boundaries of small molecule medicines with generative design. News provided by. After three years of internal development, Expedition is building a generative AI platform for covalent drug discovery, supported by a $50M initial commitment from Flagship Pioneering Multi-target exploration agreement in prostate cancer initiated under Flagship's strategic partnership with Pfizer CAMBRIDGE, Mass., Oct. 22, 2025 /PRNewswire/ - Flagship Pioneering, a scientific innovation engine for transformative platforms and products, today unveiled Expedition Medicines(TM), a company pioneering generative covalent chemistry to expand the boundaries of medicine. Following three years of in-house development, Flagship has committed an initial $50 million to support scaling Expedition's platform for generating small molecule medicines to any target and to further develop its discovery programs in oncology, immunology, and other well-defined diseases. In addition, Expedition recently initiated a multi-target exploration agreement to identify novel therapeutic candidates for prostate cancer under Flagship's strategic collaboration with Pfizer. "Today, the majority of proteins known to be involved in disease have no medicines that can reach them. By harnessing AI and quantum covalent chemistry to rewrite what's possible in drug design, Expedition is transforming these undruggable proteins into tractable targets," said Noubar Afeyan, Ph.D., Founder and CEO of Flagship Pioneering and Co-Founder and board director of Expedition Medicines. "Expedition is able to explore entirely new territory thanks to a unique insight from the quantum chemistry of protein-small molecule interactions, generative AI, and a team that bridges medicinal chemistry, artificial intelligence, and therapeutic development to redefine the drug discovery paradigm." Proteins with smooth surfaces have been considered undruggable because they lack the features for small molecules to latch onto and reversibly bind. Rather than this traditional "binding-first" approach, Expedition's approach is driven by its discovery of a "reaction-first" covalent chemical insight, where quantum interactions between small molecules and reactive parts of protein surfaces enable high potency binding even in shallow pockets of proteins. Grounded in this insight, Expedition is building a quantum chemistry AI platform that is fueled by an industry-leading chemoproteomic screening and data generation engine. The platform has enabled Expedition to access new protein targets, create high-quality quantitative molecular interaction data at scale, and train generative chemistry models to deliver de novo small molecules that effectively interact with the most elusive targets in the proteome, such as transcription factors, adaptor proteins, regulators, and protein-protein interfaces - mechanisms that have been implicated as central regulators of a wide range of diseases. "AI is transforming biology by learning the grammar of proteins and DNA. At Expedition, we are pioneering the same leap for small molecules grounded in the quantum chemistry of covalent interactions and fueled by unprecedented experimental data," said Molly Gibson, Ph.D., Co-Founder, CEO, and board director of Expedition and Origination Partner at Flagship Pioneering. "Our models are learning the rules of how molecules react and bind to any protein surface in order to make small molecule programmability a reality." Expedition has initiated research to identify new potential therapeutic candidates for prostate cancer as part of Flagship's strategic partnership with Pfizer, which seeks to create a pipeline of innovative medicines. The research, which is subject to the terms of the 2023 agreement between Flagship and Pfizer, will leverage Expedition's platform in an effort to identify novel targeted molecules for previously undruggable targets with known correlation to prostate cancer disease progression and treatment resistance. Together with Afeyan and Gibson, Expedition is led by Nathan Stebbins, Ph.D., Co-Founder and Chief Strategy Officer and Senior Principal at Flagship Pioneering; Dean Stamos, Ph.D., Co-Founder and CSO - Chemistry & Proteomics and Flagship Science Partner; Todd Kinsella, Ph.D., CSO - Drug Discovery and Translation and Flagship Science Partner; Henry van den Bedem, Ph.D., Chief Technology Officer; and Marie Yurkovich, Ph.D., Co-Founder and Head of Strategy and Operations at Expedition and Operating Principal at Flagship. Kinsella and Stamos previously led biology and chemistry innovation, respectively, at Vividion Therapeutics, and van den Bedem previously led Machine Learning at Atomwise. Geoffrey von Maltzahn, Ph.D., Co-Founder of Expedition and General Partner at Flagship Pioneering, will serve on the company's board. About Expedition Medicines Expedition Medicines is building AI to expand the boundaries of medicine. Its quantum chemistry AI platform, powered by an industry-leading chemoproteomics data generation engine, learns the rules of molecular reactivity to generate small molecule drugs against disease-driving proteins that have long been considered undruggable. The platform has enabled the creation of a pipeline of potential first-in-class therapies across oncology, immunology, and other well-defined diseases. Expedition was founded by Flagship Pioneering in 2022. For more, visit www.expeditionmedicines.com and LinkedIn. About Flagship Pioneering Flagship Pioneering invents and builds platform companies, each with the potential for multiple products that transform human health, sustainability and beyond. Since its launch in 2000, Flagship has originated and fostered more than 100 scientific ventures, operating with $14 billion of assets under its direction as of its latest capital raise, announced in July 2024. The current Flagship ecosystem comprises more than 40 companies, including Foghorn Therapeutics, Generate Biomedicines, Inari, Indigo Agriculture, Lila Sciences, Moderna, Sana Biotechnology, Tessera Therapeutics and Valo Health. SOURCE Flagship Pioneering